|
Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3. |
|
|
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; GamaMabs Pharma; Genentech/Roche; Genmab; NCCN; Oncolytics; OncoMed; Sotio; Tesaro |
Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech |
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group |
|
|
|
Research Funding - AstraZeneca (Inst); Immunovaccine (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
Other Relationship - AstraZeneca; Clovis Oncology; Clovis Oncology; Merck; Tesaro |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; ImmunoGen; Merck; PharmaMar; Roche; Takeda; Tesaro |
Travel, Accommodations, Expenses - PharmaMar; Roche |
|
|
Consulting or Advisory Role - Clovis Oncology; Clovis Oncology; Clovis Oncology; Immunogen; Mateon Therapeutics; Mateon Therapeutics; Tesaro; Tesaro |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genmab/Seattle Genetics; ImmunoGen; PharmaMar; Roche; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche; Tesaro |
|
|
Consulting or Advisory Role - Precision Oncology; Shire; Specialised Therapeutics |
|
|
Honoraria - AstraZeneca; PharmaMar; Roche/Genentech; Tesaro |
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech; Takeda; Tesaro |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - Abbvie |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Immunogen (Inst); Lilly (Inst); Millennium (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Clovis Oncology; Pharmamar; Tesaro |
Consulting or Advisory Role - AstraZeneca; Biocad; Clovis Oncology; GamaMabs Pharma; Gritstone Bio; pfizer; Seagen; Tesaro |
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Genentech (Inst); inivata (Inst); Merus (Inst); MSD Oncology (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Consulting or Advisory Role - Clovis Oncology |
Speakers' Bureau - AstraZeneca; Bard/Davol; Clovis Oncology; Intuitive Surgical; Tesaro |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Clovis Oncology |
Speakers' Bureau - AstraZeneca; Lilly; PharmaMar; Pierre Fabre; Roche |
Travel, Accommodations, Expenses - Lilly; Roche |
|
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen |
Speakers' Bureau - Novartis |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Roche |
|
|
Honoraria - Abbvie; Ambry Genetics; AstraZeneca; BioMedical Insights; Clovis Oncology; Genentech/Roche; GOG Foundation; Immunogen; Janssen Oncology; Marker Therapeutics; Myriad Genetics; Novocure; OncLive; OncoQuest; Prime Oncology; Targeted Oncology; Tesaro; Translational Genomics Research Institute |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Clovis Oncology; Genentech/Roche; GOG Foundation; Immunogen; Janssen Oncology; Myriad Genetics; Novocure; OncoQuest; Tesaro; Translational Genomics Research Institute |
Research Funding - Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Genmab (Inst); Immunogen (Inst); Immunogen (Inst); Janssen Research & Development (Inst); PharmaMar (Inst); Regeneron (Inst); Seagen (Inst); Stem CentRx (Inst); Tesaro (Inst); TRACON Pharma (Inst); VentiRx (Inst) |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
|
|
Employment - Clovis Oncology |
Stock and Other Ownership Interests - Clovis Oncology |
|
|
Honoraria - AstraZeneca/MedImmune; Roche |
Consulting or Advisory Role - Artios; AstraZeneca/MedImmune; Clovis Oncology; Cristal Therapeutics; Merck; Pfizer; Seagen; Tesaro |
Speakers' Bureau - Clovis Oncology; Pfizer |
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst) |